191 related articles for article (PubMed ID: 37980807)
21. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
22. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
23. The role of ABC transporters in clinical practice.
Leonard GD; Fojo T; Bates SE
Oncologist; 2003; 8(5):411-24. PubMed ID: 14530494
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
26. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
Zhang Q; Li F
Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
[TBL] [Abstract][Full Text] [Related]
27. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
[TBL] [Abstract][Full Text] [Related]
28. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
29. Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment.
Lee T; Kim KS; Na K
J Control Release; 2023 Feb; 354():268-278. PubMed ID: 36634708
[TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
31. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y
Expert Opin Ther Targets; 2017 May; 21(5):511-530. PubMed ID: 28335655
[TBL] [Abstract][Full Text] [Related]
33. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
34. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
35. Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil.
Wang X; Wang Z; Wang K; Gao M; Zhang H; Xu X
Biomed Chromatogr; 2021 Feb; 35(2):e4976. PubMed ID: 32852057
[TBL] [Abstract][Full Text] [Related]
36. Investigational ABC transporter inhibitors.
Falasca M; Linton KJ
Expert Opin Investig Drugs; 2012 May; 21(5):657-66. PubMed ID: 22493979
[TBL] [Abstract][Full Text] [Related]
37. Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation.
Dhakne P; Pillai M; Mishra S; Chatterjee B; Tekade RK; Sengupta P
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188906. PubMed ID: 37172652
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
39. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
Breuninger LM; Paul S; Gaughan K; Miki T; Chan A; Aaronson SA; Kruh GD
Cancer Res; 1995 Nov; 55(22):5342-7. PubMed ID: 7585598
[TBL] [Abstract][Full Text] [Related]
40. The Effects of Traditional Chinese Medicine on P-Glycoprotein-Mediated Multidrug Resistance and Approaches for Studying the Herb-P-Glycoprotein Interactions.
Cao Y; Shi Y; Cai Y; Hong Z; Chai Y
Drug Metab Dispos; 2020 Oct; 48(10):972-979. PubMed ID: 32816867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
